Physician profile
David B Sutherland
NPI 1619976909
$13,392.84
in general payments reported to CMS, 2019-2025
47 companies · $2,523 in 2025
The $2,523 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,474 · 2020: $726 · 2021: $1,041 · 2022: $2,540 · 2023: $2,690 · 2024: $2,399 · 2025: $2,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,435 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,435.28 |
| Education | $176.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,558.27 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,770.97 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,069.76 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Nestle Healthcare Nutrition INC. | $805.20 | 2020-2023 | |
| Genzyme Corporation | $536.08 | 2023-2025 | |
| Pfizer INC. | $514.01 | 2019-2025 | |
| Ardelyx, INC. | $498.29 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $468.11 | 2019-2023 | Xifaxan |
| Celgene Corporation | $421.62 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $401.45 | 2024-2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $320.01 | 2019-2023 | Dificid, Zinplava |
| Regeneron Pharmaceuticals, INC. | $319.29 | 2024-2025 | Dupixent |
| Novo Nordisk INC | $287.20 | 2024-2025 | Wegovy, Ozempic |
| Janssen Scientific Affairs, LLC | $230.05 | 2024-2025 | Tremfya, Stelara |
| Ferring Pharmaceuticals INC. | $217.21 | 2019-2024 | Rebyota |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.